Valneva-Pfizer Lyme vaccine misses primary endpoint but shows promising secondary results.

Valneva and Pfizer's Lyme disease vaccine candidate failed to meet the primary endpoint in the Phase 3 VALOR trial due to fewer cases than expected. However, a secondary analysis showed clinically meaningful efficacy, with about 73-75% effectiveness in reducing confirmed Lyme disease cases compared to placebo. Pfizer remains confident and plans to submit the vaccine for regulatory approval. Meanwhile, Valneva's stock is under pressure, trading significantly below key moving averages and near 52-week lows, reflecting market concerns despite the vaccine's potential.